You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中金:上調百濟神州(6160.HK)目標價至130.38港元 評級“跑贏大市”
格隆匯 11-04 11:19

中金髮表報告表示,百濟神州(06160.HK)上週五公佈獲美國安進藥廠(Amgen)斥資27億美元20.5%股權,該行認為將有助緩解百濟神州的資金壓力及加快產品研發時間表,且對其國際市場之擴張情況有信心。

報告又指,與安進藥廠之合作,將有助百濟神州擴張其產品種類,為長線發展奠定基礎。由於協議尚未實施,該行維持其2019至2020年銷售預測為3.48億美元及3.91億美元,按年升75.5%及12.3%,以及每股盈利預測分別為0.84美元及0.91美元,維持“跑贏大市”評級,目標價調升38%至130.38港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account